Recombinant Plasma Proteins Market, By Type (Chinese Hamster Ovary (CHO) Cell Line, Baby Hamster Kidney (BHK) Cell Line, Human Embryonic Kidney (HEK) Cell Line, and Others), By Application (Hemophilia A, Hemophilia B, Von Willebrand Disease, and Others), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Trends, Analysis and Forecast till 2032

Recombinant plasma proteins refer to proteins that are produced through genetic engineering techniques, DNA technology used for development of novel therapies for treatment of chronic diseases such as cancer. Recombinant proteins are used in various areas such as anemia, diabetes, rheumatoid arthritis, and others.

Dividing this target market into segments:

Recombinant Plasma Proteins Market is segmented based on Type, Application and Region.

Type Insight

On the basis of Type, the target market is segmented into Chinese Hamster Ovary (CHO) Cell Line, Baby Hamster Kidney (BHK) Cell Line, Human Embryonic Kidney (HEK) Cell Line, and Others

Application Insight

On the basis of Application, the target market is segmented into Hemophilia A, Hemophilia B, Von Willebrand Disease, and Others

Regional Insights:

On region the target market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

• North America market is estimated to witness a significantly high revenue share over the forecast period due to increase investment, increasing prevalence of chronic diseases, developed healthcare infrastructure, presence of strong pharmaceutical companies and use of analytical instrument in drug discovery and  development.
• Asia Pacific market is estimated to witness a fastest revenue share over the forecast period due to improving healthcare infrastructure, rising cases and awareness regarding various chronic diseases, investment in healthcare sector and growing pharmaceutical expansion.

Recombinant Plasma Proteins Market Report Scope:

Segments Covered in the Report:

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2022 to 2032.

The key players operating the Recombinant Plasma Proteins Market includes, CSL Limited, Shire (Takeda Pharmaceutical Company Limited), Octapharma, Novo Nordisk, Bayer, Bioverativ Therapeutics (Sanofi), Aptevo Therapeutics, Pharming Group, Pfizer Inc. 

The New Launched Product News,

• In November 2023,  Takeda announced the approval of ADZYNMA by U.S. Food and Drug Administration (FDA) for the prophylactic and on-demand treatment of adult and pediatric patients with congenital thrombotic thrombocytopenic purpura (cTTP). ADZYNMA is the first and only FDA-approved recombinant ADAMTS13 (rADAMTS13) protein designed to address an unmet medical need in people with cTTP by replacing the deficient ADAMTS13 enzyme.
• In November 2023, GC Biopharma announced  its application for the marketing approval of "GC1109", an anthrax vaccine jointly developed by GC Biopharma and the Korea Disease Control and Prevention Agency (KDCA), to the Korean Ministry of Food and Drug Safety (MFDS). 'GC1109' contains protective antigen (PA) as its active pharmaceutical ingredients produced by recombinant DNA technology which delivers 2 types of proteins that comprise anthrax toxin, namely, lethal factor (LF) and edema factor (EF), into cells. If approved, "GC1109" will be the world's first recombinant anthrax vaccine.